Summit Therapeutics PLC (LSE:SUMM) - Share price - Overview

Stock Report

Summit Therapeutics PLC SUMM

Last Price
GBX177.50

Day Change
0.00|0.00%

As of 19/01/2018
10:45:43 GMT | GBX
Minimum 15 Minutes Delay.

Last Close177.50p
Day Range175.50 - 175.50
Mkt Cap130.60Mil
52-Wk Range140.00 - 269.70
Yield %0.00
ISINGB00BN40HZ01
Volume556
P/E-5.07
P/S47.42
P/CF8.99

Share Price

Total Returns 19/01/2018

 Chg (%)  
More ...
Summit Therapeutics PLC9.23 
FTSE 100 TR GBP2.61
 
Financials
201520162017
More ...
Income Statement
Turnover0.000.002.30
Operating Profit-12.71-20.18-24.85
Net Profit-11.36-17.09-21.37
Reported EPS-29.00-29.00-35.00
Balance Sheet
Current Assets15.1920.8633.34
Non Current Assets4.204.224.25
Total Assets19.4025.0837.59
Current Liabilities3.773.2110.90
Total Liabilities4.433.9441.08
Total Equity14.9721.13-3.49
Cash Flow
Operating Cash Flow-11.98-18.589.14
Net Change in Cash9.244.9212.47
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2018-7.34-2.46--72.24---
2019-21.65-13.91--12.76---

Company Profile

Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

Sector

Drug Manufacturers - Specialty & Generic

Market Position

856 of 1835 Companies

Index

FTSE AIM All Share

Outlook

(06/12/2017) no outlook statement

Next Event 31/01/2018

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-13.1114.145.53
Div Yld (E)0.004.064.03
PEG (E)0.00-0.460.98
ROCE2,348.30179.53180.33
Op Mrgn-1,078.69-8.37-126.27
EPS Grwth0.005.7922.39
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Frank Armstrong
Chief Executive OfficerMr. Glyn Edwards
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.